Lexeotherapeutics chief legal officer sells $9,271 in stock

Jenny Robertson, the Chief Legal Officer of Lexeo Therapeutics Inc. (NASDAQ:LXEO), recently sold shares of the company’s common stock amid challenging market conditions, with the stock trading near its 52-week low of $3.84 and down over 68% in the past six months. According to a recent SEC filing, Robertson sold 2,101 shares at an average price of $4.413 per share, totaling approximately $9,271. The transaction was carried out to cover tax obligations related to the release of restricted stock units. Following this transaction, Robertson holds 57,899 shares, which include 54,062 restricted stock units. InvestingPro analysis suggests the company is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.

In other recent news, Lexeo Therapeutics announced the appointment of Dr. Kyle Rasbach as their new Chief Financial Officer. Dr. Rasbach brings a wealth of experience in life sciences and financial management, having previously held roles at Zentalis Pharmaceuticals, Eventide Asset Management, and T. Rowe Price. This strategic appointment comes as Lexeo prepares for significant advancements in its gene therapy programs, particularly in the areas of cardiovascular diseases and APOE4-associated Alzheimer’s disease. The company is actively working towards pivotal studies, informed by early proof-of-concept data. CEO R. Nolan Townsend expressed optimism about Dr. Rasbach’s appointment, emphasizing his strong track record in healthcare and life sciences investments. Dr. Rasbach is eager to contribute to Lexeo’s mission of developing life-changing therapies for patients with genetic conditions. These developments are part of Lexeo’s broader strategy to advance its pipeline and achieve clinical trial milestones. The company has acknowledged that its forward-looking statements involve risks and uncertainties, as detailed in their filings with the U.S. Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.